Lasseter KC - Search Results

1

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.

Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Mistry GC, et al. Among authors: lasseter kc. J Clin Pharmacol. 2008 May;48(5):592-8. doi: 10.1177/0091270008316885. Epub 2008 Mar 19. J Clin Pharmacol. 2008. PMID: 18353996 Clinical Trial.

2

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.

Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA. Herman GA, et al. J Clin Pharmacol. 2006 Aug;46(8):876-86. doi: 10.1177/0091270006289850. J Clin Pharmacol. 2006. PMID: 16855072 Clinical Trial.

3

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. Vincent SH, et al. Drug Metab Dispos. 2007 Apr;35(4):533-8. doi: 10.1124/dmd.106.013136. Epub 2007 Jan 12. Drug Metab Dispos. 2007. PMID: 17220239 Clinical Trial.

4

Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.

Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G. Krishna R, et al. J Clin Pharmacol. 2007 Feb;47(2):165-74. doi: 10.1177/0091270006296523. J Clin Pharmacol. 2007. PMID: 17244767 Clinical Trial.

5

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Mistry GC, Luo WL, Liu Q, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman GA, Wagner JA, Krishna R. Bergman A, et al. Biopharm Drug Dispos. 2007 Sep;28(6):307-13. doi: 10.1002/bdd.559. Biopharm Drug Dispos. 2007. PMID: 17571284 Clinical Trial.

6

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R. Bergman A, et al. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. doi: 10.1002/bdd.560. Biopharm Drug Dispos. 2007. PMID: 17575559 Clinical Trial.

7

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. Among authors: lasseter kc. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.

8

Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.

Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA. Mistry GC, et al. Among authors: lasseter kc. J Clin Pharmacol. 2007 Aug;47(8):951-61. doi: 10.1177/0091270007303764. J Clin Pharmacol. 2007. PMID: 17660480 Clinical Trial.

9

Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.

Schwartz JI, Thach C, Lasseter KC, Miller J, Hreniuk D, Hilliard DA, Snyder KM, Gertz BJ, Gottesdiener KM. Schwartz JI, et al. Among authors: lasseter kc. J Clin Pharmacol. 2007 Dec;47(12):1521-31. doi: 10.1177/0091270007307878. Epub 2007 Oct 9. J Clin Pharmacol. 2007. PMID: 17925592 Clinical Trial.

10

Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.

Schwartz JI, Dunbar S, Yuan J, Li S, Miller DL, Rosko K, Johnson-Levonas AO, Lasseter KC, Wagner JA. Schwartz JI, et al. Among authors: lasseter kc. J Clin Pharmacol. 2009 Jan;49(1):72-9. doi: 10.1177/0091270008325930. Epub 2008 Oct 20. J Clin Pharmacol. 2009. PMID: 18936284 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

153 results

Search Page